Overview

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

Status:
Terminated

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

This was a randomized, double-blind, placebo-controlled phase 2 clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who received treatment with capecitabine in combination with ruxolitinib versus those who received treatment with capecitabine alone.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Capecitabine